S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
Log in
NASDAQ:HOTH

Hoth Therapeutics Stock Forecast, Price & News

$1.72
+0.01 (+0.58 %)
(As of 12/2/2020 04:34 PM ET)
Add
Compare
Today's Range
$1.66
Now: $1.72
$1.74
50-Day Range
$1.65
MA: $1.76
$1.88
52-Week Range
$1.60
Now: $1.72
$7.25
Volume145,224 shs
Average Volume417,570 shs
Market Capitalization$23.11 million
P/E RatioN/A
Dividend YieldN/A
Beta1.12
Hoth Therapeutics, Inc., a biopharmaceutical company, focuses on developing therapies for dermatological disorders. The company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. It intends to use the BioLexa Platform to develop two topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures. The company has license agreements with the George Washington University; the University of Maryland Baltimore; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Zylö Therapeutics, Inc.; Chelexa BioSciences, Inc.; and the University of Cincinnati. Hoth Therapeutics, Inc. was founded in 2017 and is headquartered in New York, New York.

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.46 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HOTH
CUSIPN/A
CIKN/A
Phone646-756-2997
Employees2

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.40 per share

Profitability

Net Income$-7,700,000.00

Miscellaneous

Market Cap$23.11 million
Next Earnings Date12/8/2020 (Estimated)
OptionableNot Optionable
$1.72
+0.01 (+0.58 %)
(As of 12/2/2020 04:34 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HOTH News and Ratings via Email

Sign-up to receive the latest news and ratings for HOTH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Hoth Therapeutics (NASDAQ:HOTH) Frequently Asked Questions

How has Hoth Therapeutics' stock price been impacted by Coronavirus?

Hoth Therapeutics' stock was trading at $3.84 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, HOTH stock has decreased by 55.2% and is now trading at $1.72.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than Hoth Therapeutics?

Wall Street analysts have given Hoth Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Hoth Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Hoth Therapeutics' next earnings date?

Hoth Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, December 8th 2020.
View our earnings forecast for Hoth Therapeutics
.

How were Hoth Therapeutics' earnings last quarter?

Hoth Therapeutics, Inc. (NASDAQ:HOTH) announced its quarterly earnings data on Wednesday, May, 13th. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by $0.01.
View Hoth Therapeutics' earnings history
.

Are investors shorting Hoth Therapeutics?

Hoth Therapeutics saw a decline in short interest in November. As of November 15th, there was short interest totaling 12,600 shares, a decline of 35.7% from the October 31st total of 19,600 shares. Based on an average daily trading volume, of 195,200 shares, the short-interest ratio is currently 0.1 days. Currently, 0.1% of the shares of the company are sold short.
View Hoth Therapeutics' Short Interest
.

Who are some of Hoth Therapeutics' key competitors?

What other stocks do shareholders of Hoth Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hoth Therapeutics investors own include Citius Pharmaceuticals (CTXR), Ocugen (OCGN), Fulcrum Therapeutics (FULC), Heat Biologics (HTBX), Tonix Pharmaceuticals (TNXP), AIM ImmunoTech (AIM), Aytu BioScience (AYTU), Gilead Sciences (GILD), iBio (IBIO) and Nabriva Therapeutics (NBRV).

Who are Hoth Therapeutics' key executives?

Hoth Therapeutics' management team includes the following people:
  • Mr. Robb Knie, Pres, CEO & Chairman (Age 51, Pay $525k)
  • Ms. Jane H. Behrmann, VP of Operations (Age 35, Pay $123.78k)
  • Mr. David S. Briones, Chief Financial Officer (Age 44)
  • Dr. Stefanie Johns Ph.D., Chief Scientific Officer

When did Hoth Therapeutics IPO?

(HOTH) raised $8 million in an initial public offering (IPO) on Friday, February 15th 2019. The company issued 1,300,000 shares at a price of $5.50-$6.50 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO.

What is Hoth Therapeutics' stock symbol?

Hoth Therapeutics trades on the NASDAQ under the ticker symbol "HOTH."

How do I buy shares of Hoth Therapeutics?

Shares of HOTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Hoth Therapeutics' stock price today?

One share of HOTH stock can currently be purchased for approximately $1.72.

How big of a company is Hoth Therapeutics?

Hoth Therapeutics has a market capitalization of $23.11 million. Hoth Therapeutics employs 2 workers across the globe.

What is Hoth Therapeutics' official website?

The official website for Hoth Therapeutics is www.hoththerapeutics.com.

How can I contact Hoth Therapeutics?

Hoth Therapeutics' mailing address is 1 Rockefeller Plaza Suite 1039, New York NY, 10020. The company can be reached via phone at 646-756-2997 or via email at [email protected]

This page was last updated on 12/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.